Physician profile
Peter Zhou
NPI 1619464211
$4,848.19
in general payments reported to CMS, 2019-2025
14 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,652 · 2024: $1,230 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138 · Travel and Lodging: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.11 |
| Travel and Lodging | $1,710.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,921.63 | 2023-2025 | N/A, Capri Corpectomy Cage System, Bio Dbm |
| Globus Medical, INC. | $1,322.48 | 2025 | Excelsius Gps, Hedron, Modulus |
| Cerapedics INC. | $428.93 | 2023-2024 | I-Factor Peptide Enhanced Bone Graft |
| E.R. Squibb & Sons, L.L.C. | $223.46 | 2025 | Breyanzi, Camzyos |
| Zimmer Biomet Holdings, INC. | $193.57 | 2023 | Mymobility Platform |
| Lilly USA, LLC | $131.56 | 2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $124.99 | 2024 | Inpefa |
| Glaxosmithkline, LLC. | $123.52 | 2024 | Arexvy |
| Novo Nordisk INC | $118.42 | 2024 | |
| Orthofix Medical, INC. | $55.65 | 2024 | Mariner Deformity |
| Ferring Pharmaceuticals INC. | $32.61 | 2025 | Euflexxa |
| Kyowa Kirin, INC. | $24.50 | 2025 | |
| Merck Sharp & Dohme LLC | $21.87 | 2025 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.